Search

Displaying results 1361 - 1370 of 10000 in total
  1. Drug

    Ensartinib

    go.drugbank.com/drugs/DB14860
    ApprovedInvestigational

    [A265030] The drug is 10-fold more potent in the inhibition of the growth of ALK-positive lung cancer cell lines when compared to [crizotinib]. … [A273963, A273958] Ensartinib is a first-line treatment for anaplastic lymphoma kinase (ALK)-mutated non-small cell lung cancer (NSCLC).

  2. Drug

    Vildagliptin

    go.drugbank.com/drugs/DB04876
    ApprovedInvestigational

    [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea … , or a thiazolidinedione in patients with inadequate glycemic control following monotherapy.

    Mixtures: Vildagliptin/Metformin 1A Pharma 50 mg/850 mg – Filmtabletten, Vildagliptin/Metformin 1A Pharma 50 mg/1000 mg - FilmtablettenCategories: Drugs Used in Diabetes, DPP-IV Inhibitors
  3. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension.

    Products: MOXONIDIN 1A PHARMA 0.2MG, MOXONIDIN 1A PHARMA 0.3MG
  4. Drug

    Ferrous fumarate

    go.drugbank.com/drugs/DB14491
    ApprovedInvestigational

    Used in treatment of iron deficiency anemia.

    Mixtures: Vc II, Iron II
  5. Drug

    Chromic chloride

    go.drugbank.com/drugs/DB09129
    Approved

    Chromic chloride, for injection, is a sterile, nonpyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN).

    Mixtures: One-A-day Advance Men's, M T E 4 Concentrate InjCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    Poloxamer 188

    go.drugbank.com/drugs/DB11333
    Approved

    Poloxamer 188 (P188) is a nonionic block linear copolymer that exhibits rheologic, anti-thrombotic, anti-inflammatory, and cytoprotective activities in various tissue injury models [A33121]. … The ability of P188 in attenuating membrane damage and cell injury has been demonstrated in a variety of _in vivo_ and _in vitro_ models [A27218].

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [A262551] It is produced using recombinant DNA technology in CHO cell lines and is marketed by Hipra Human Health S.L. for the European market. … [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907]

  8. Drug

    Aloe vera leaf

    go.drugbank.com/drugs/DB13906
    ApprovedInvestigational

    While aloe vera has a long history of commercial uses, it is still widely used in cosmetic, food and pharmaceutical products. … It is a perennial succulent xerophyte with elongated leaves that contain a clear gel.

    Mixtures: Lax-ease, C Ottways Lax TabSynonyms: Lu hui ye, Lu hui (aloe vera)
  9. Drug

    Nadolol

    go.drugbank.com/drugs/DB01203
    ApprovedInvestigational

    [L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and … Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.

  10. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]